Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1999 May; 80(3-4): 519–525.
Published online 1999 May 1. doi:  10.1038/sj.bjc.6690387
PMCID: PMC2362342

c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates


The detection of specific genetic alterations in breast cancer is useful for diagnosing, predicting prognosis and planning preoperative treatment. c-erbB2/neu overexpression is usually detected by immunocytochemistry (ICC), although this technique is neither completely reproducible nor highly reliable, owing to specimen and methodologic variability and antibody sensitivity. Here, we combine two well-established techniques, fine-needle aspiration (FNA) and fluorescence in situ hybridization (FISH), to detect c-erbB2/neu amplification in patients candidate to primary chemotherapy and, in part, previously analysed for c-erbB2/neu overexpression. Sixty smears from FNA were used to simultaneously detect c-erbB2/neu and chromosome 17 centromere. FISH was successful in 58 cases and detected 24 amplified cases, three of which were negative by immunophenotyping, 28 negative cases, with evidence of two normal c-erbB2/neu/ signals, two cases with deletion of c-erbB2/neu, and four cases with polysomy, thus providing more reliable and informative results than ICC. This study underlines the advantages offered by the FNA and FISH combination which are two rapid, reliable, simple and informative techniques, to analyse one of the most important genetic markers for predicting prognosis and chemotherapy planning for breast carcinoma in particular in the light of the recently proposed trials of primary chemotherapy. © 1999 Cancer Research Campaign

Keywords: breast carcinoma, FNA, c-erbB2/neu, FISH, immunocytochemistry, primary chemotherapy

Full Text

The Full Text of this article is available as a PDF (121K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alsabeh R, Wilson CS, Ahn CW, Vasef MA, Battifora H. Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol. 1996 Apr;9(4):439–444. [PubMed]
  • Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998 Apr;16(4):1340–1349. [PubMed]
  • Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990 Oct 3;82(19):1539–1545. [PubMed]
  • Cajulis RS, Frias-Hidvegi D, Yu GH, Eggena S. Detection of numerical chromosomal abnormalities by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes on archival cytologic samples. Diagn Cytopathol. 1996 Mar;14(2):178–181. [PubMed]
  • Corkill ME, Katz R. Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol. 1994;11(3):250–254. [PubMed]
  • De Potter CR, Schelfhout AM. The neu-protein and breast cancer. Virchows Arch. 1995;426(2):107–115. [PubMed]
  • De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, Eechaute W, Roels H. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer. 1989 Dec 15;44(6):969–974. [PubMed]
  • Frigo B, Pilotti S, Zurrida S, Ermellino L, Manzari A, Rilke F. Analysis of estrogen and progesterone receptors on preoperative fine-needle aspirates. Breast Cancer Res Treat. 1995;33(2):179–184. [PubMed]
  • Gnant MF, Blijham GH, Reiner A, Schemper M, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R. Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results. Ann Oncol. 1993 Sep;4(8):643–650. [PubMed]
  • Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1995 Oct 4;87(19):1441–1445. [PubMed]
  • Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul;10(7):1049–1056. [PubMed]
  • Hansen R, Reddel R, Braithwaite A. The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis. Oncogene. 1995 Dec 21;11(12):2535–2545. [PubMed]
  • Harwerth IM, Wels W, Schlegel J, Müller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer. 1993 Dec;68(6):1140–1145. [PMC free article] [PubMed]
  • Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165–184. [PubMed]
  • Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321–5325. [PMC free article] [PubMed]
  • Lavarino C, Corletto V, Mezzelani A, Della Torre G, Bartoli C, Riva C, Pierotti MA, Rilke F, Pilotti S. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer. 1998;77(1):125–130. [PMC free article] [PubMed]
  • Lichter P, Tang CJ, Call K, Hermanson G, Evans GA, Housman D, Ward DC. High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. Science. 1990 Jan 5;247(4938):64–69. [PubMed]
  • Ljung BM, Chew K, Deng G, Matsumura K, Waldman F, Smith H. Fine needle aspiration techniques for the characterization of breast cancers. Cancer. 1994 Aug 1;74(3 Suppl):1000–1005. [PubMed]
  • Lönn U, Lönn S, Nilsson B, Stenkvist B. Prognostic significance of c-erb-B2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis. Breast Cancer Res Treat. 1996;39(2):213–220. [PubMed]
  • Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. [PubMed]
  • Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994 Nov 4;266(5186):807–810. [PubMed]
  • Midulla C, Giovagnoli MR, Valli C, Vecchione A. Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma. Anal Quant Cytol Histol. 1995 Jun;17(3):157–162. [PubMed]
  • Moll UM, Ostermeyer AG, Ahomadegbe JC, Mathieu MC, Riou G. p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum Pathol. 1995 Dec;26(12):1293–1301. [PubMed]
  • Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5;330(18):1260–1266. [PubMed]
  • Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995 Jun 15;10(12):2435–2446. [PubMed]
  • Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994 May 15;54(10):2771–2777. [PubMed]
  • Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997 Aug;15(8):2894–2904. [PubMed]
  • Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991 Aug 19;49(1):44–49. [PubMed]
  • Sauter G, Feichter G, Torhorst J, Moch H, Novotna H, Wagner U, Dürmüller U, Waldman FM. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol. 1996 Mar-Apr;40(2):164–173. [PubMed]
  • Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998 Feb;16(2):462–469. [PubMed]
  • Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science. 1991 Nov 22;254(5035):1153–1160. [PubMed]
  • Troncone G, Zeppa P, Fulciniti F, Di Benedetto G, Lobresco MA, De Divitiis B, Vetrani A, Palombini L. C-erbB-2 expression and DNA ploidy status in breast cancer cells obtained by fine needle aspiration (FNA). Cytopathology. 1993;4(4):195–205. [PubMed]
  • Troncone G, Panico L, Vetrani A, de Divitiis B, Zeppa P, Fulciniti F, Pettinato G, Palombini L. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol. 1996 Mar;14(2):135–139. [PubMed]
  • Von Hoff DD, McGill JR, Forseth BJ, Davidson KK, Bradley TP, Van Devanter DR, Wahl GM. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8165–8169. [PMC free article] [PubMed]
  • Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996 Jan;2(1):72–79. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...